Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer

This trial is a phase II, randomized, open label study designed to evaluate safety, tolerability and efficacy of CC-1, a bispecific antibody (bsAb) with PSMAxCD3 specificity, and of VACXS15-PC01, a prostate cancer (PC)-specific multi-peptide vaccine, both administered as single agent or in combination to patients affected with biochemical recurrence (BCR) of PC after local therapy with curative intent. Patients will not receive other treatments during trial participation.

Trial Details

NCT ID
NCT07860047
Phase
PHASE2
Sponsor
University Hospital Tuebingen
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • PSMAxCD3, bispecific antibody CC-1
  • Multipeptide Vaccine VAC-XS15-PC01
Locations (sample)
  • Heidelberg, Baden-Wurttemberg, Germany|49.40768,8.69079
  • Tübingen, Baden-Wurttemberg, Germany|48.52266,9.05222
  • Berlin, Beriln, Germany|52.52437,13.41053
  • Essen, North Rhine-Westphalia, Germany|51.45657,7.01228

Key Eligibility Criteria

  • Understand and voluntarily sign an IC document prior to any study related assessments/procedures
  • Understand and voluntarily sign an IC document prior to any study related assessments/procedures
  • Patient is able to understand and comply with the protocol for the duration of the study including treatment and scheduled visits and examinations
  • Men aged ≥ 18 and ≤80 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →